Dr. Sulaiman Al Habib Medical Journal

Volume 1, Issue 1-2, June 2019, Pages 23 - 26

Prospects for the Management of Sepsis in an Era of Personalised Medicine

Authors
Jonathan Cohen*
Department of Medicine, Brighton and Sussex Medical School, University of Sussex, East Sussex, Brighton, UK

Peer review under responsibility of the Dr. Sulaiman Al Habib Medical Services Group Company

Corresponding Author
Jonathan Cohen
Received 8 March 2019, Accepted 8 March 2019, Available Online 28 March 2019.
DOI
10.2991/dsahmj.k.190319.001How to use a DOI?
Keywords
Genomics; omics; personalised medicine; precision medicine; sepsis
Abstract

Sepsis remains an unmet medical need, and sustained attempts by intensivists have indeed yielded an incremental improvement in outcomes. However, despite many attempts to introduce novel therapeutic molecules, there has been no step change in survival rates. Precision (or personalised) medicine (PM) has emerged in recent years as an approach that seeks to make use of person-specific, real-time data to choose a therapeutic regimen designed specifically for the individual patient. PM has been used most successfully in oncology where chemotherapy regimens can be tailored to specific cancer genotypes. This review considers the options for using PM to improve the outcome in sepsis. There are several challenges. The nature of omics technology is that it involves multiple analytes, each of which usually has a very modest effect; hence large numbers of patients need to be studied. Sophisticated bioinformatic analysis is required that is not suitable for routine clinical use. Sepsis is a fast-moving situation and it is likely that PM profiles would change quickly. This is a huge challenge, since it requires the physician to accurately place the patient in the appropriate cohort that is relevant to the test being used. Many septic patients have comorbidities that complicate data interpretation. Finally, the nature of PM is that it is designed for the individual patient, or at least for a homogeneous group of patients who share specific characteristics. As we have seen, that is difficult to achieve in sepsis, which is a heterogeneous condition. PM is likely to be harder to use in sepsis than in some other clinical settings.

Copyright
© 2019 Dr. Sulaiman Al Habib Medical Group. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Dr. Sulaiman Al Habib Medical Journal
Volume-Issue
1 - 1-2
Pages
23 - 26
Publication Date
2019/03/28
ISSN (Online)
2590-3349
ISSN (Print)
2666-819X
DOI
10.2991/dsahmj.k.190319.001How to use a DOI?
Copyright
© 2019 Dr. Sulaiman Al Habib Medical Group. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Jonathan Cohen
PY  - 2019
DA  - 2019/03/28
TI  - Prospects for the Management of Sepsis in an Era of Personalised Medicine
JO  - Dr. Sulaiman Al Habib Medical Journal
SP  - 23
EP  - 26
VL  - 1
IS  - 1-2
SN  - 2590-3349
UR  - https://doi.org/10.2991/dsahmj.k.190319.001
DO  - 10.2991/dsahmj.k.190319.001
ID  - Cohen2019
ER  -